MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-11-2026
Innate Pharma S.A. P/CF Ratio 2011-2026 | IPHA
Annual P/CF Ratio Innate Pharma S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -6.2 | -5.29 | 12.3 | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.3 | -6.2 | 0.282 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-94.9 | $ 3.5 | -5.79 % | $ 8.42 B |  Australia |
 |
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-0.632 | - | 4.14 % | $ 49.1 M |  USA |
 |
Applied Molecular Transport
AMTI
|
-0.236 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-9.8 | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioNTech SE
BNTX
|
70.7 | $ 97.54 | 2.14 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
8 | $ 20.22 | -0.76 % | $ 945 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
4.92 | $ 1.39 | -0.43 % | $ 357 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
-0.976 | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
-0.159 | - | -39.0 % | $ 4.57 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.537 | $ 2.99 | 2.4 % | $ 4.92 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
-8.91 | $ 4.13 | 1.23 % | $ 442 M | USA |
 |
Aravive
ARAV
|
-0.928 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-612 | $ 24.23 | 0.08 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
-1.17 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-9.67 | $ 32.58 | 1.05 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.14 | $ 1.5 | 0.34 % | $ 399 M | Britain |
 |
Aptose Biosciences
APTO
|
-0.0645 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
-0.84 | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
-0.891 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.224 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-8.14 | $ 2.55 | - | $ 16 M | USA |
 |
InflaRx N.V.
IFRX
|
-3.72 | $ 1.02 | 2.0 % | $ 152 M | Germany |
 |
AstraZeneca PLC
AZN
|
13.6 | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
-0.696 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-1.8 K | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
-2.7 | - | 0.23 % | $ 488 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-765 | $ 3.83 | - | $ 258 B | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-2.48 | - | 3.16 % | $ 1.9 M | USA |
 |
Baudax Bio
BXRX
|
-0.028 | - | 0.59 % | $ 63 K | USA |
 |
Cabaletta Bio
CABA
|
-2.16 | $ 3.23 | 3.19 % | $ 325 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-6.14 | - | - | $ 2.17 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-47.3 | - | - | $ 3.45 B | USA |
 |
Aileron Therapeutics
ALRN
|
-1.71 | - | 10.36 % | $ 9.8 M | USA |